多发性硬化症的现有和新兴疗法：系统评价。
Current and emerging therapies in multiple sclerosis: a systematic review.
机构信息
University of Connecticut Health Center, Neurology Associates, 263 Farmington Ave., Farmington, CT 06030-5357, USA.
出版信息
Ther Adv Neurol Disord. 2012 Jul;5(4):205-20. doi: 10.1177/1756285612450936.
Abstract
Multiple sclerosis (MS) is a potentially disabling chronic autoimmune neurological disease that mainly affects young adults. Our understanding of the pathophysiology of MS has significantly advanced in the past quarter of a century. This has led to the development of many disease-modifying therapies (DMTs) that prevent exacerbations and new lesions in patients with relapsing remitting MS (RRMS). So far there is no drug available that can completely halt the neurodegenerative changes associated with the disease. It is the purpose of this review to provide concise information regarding mechanism of action, indications, side effects and safety of Food and Drug Administration and European Medicines Agency approved agents for MS, emerging therapies, and drugs that can be considered for off-label use in MS.
摘要
多发性硬化症（MS）是一种潜在的致残性慢性自身免疫性神经系统疾病，主要影响年轻人。在过去的四分之一个世纪里，我们对 MS 的病理生理学的理解有了显著的提高。这导致了许多疾病修饰疗法（DMTs）的发展，这些疗法可以预防复发缓解型多发性硬化症（RRMS）患者的恶化和新病变。到目前为止，还没有一种药物可以完全阻止与疾病相关的神经退行性变化。本文旨在提供有关美国食品和药物管理局和欧洲药品管理局批准的 MS 药物的作用机制、适应症、副作用和安全性的简明信息，包括新兴疗法以及可考虑在 MS 中进行标签外使用的药物。
相似文献
1
Current and emerging therapies in multiple sclerosis: a systematic review.多发性硬化症的现有和新兴疗法：系统评价。
Ther Adv Neurol Disord. 2012 Jul;5(4):205-20. doi: 10.1177/1756285612450936.
2
Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.比较复发缓解型多发性硬化症患者的疾病修正治疗的疗效和可接受性：系统评价和网络荟萃分析。
J Neurol. 2020 Dec;267(12):3489-3498. doi: 10.1007/s00415-019-09395-w. Epub 2019 May 25.
3
Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.多发性硬化症：现有和新兴的疾病修正治疗方法和治疗策略。
Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002.
4
Teriflunomide for multiple sclerosis.特立氟胺用于治疗多发性硬化症。
Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2.
5
New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.美国食品药品监督管理局（FDA）新批准的用于治疗多发性硬化症的疾病修正疗法
Clin Ther. 2015 Apr 1;37(4):691-715. doi: 10.1016/j.clinthera.2015.03.001. Epub 2015 Apr 4.
6
Update on disease-modifying therapies for multiple sclerosis.多发性硬化症疾病修正疗法的最新进展。
J Investig Med. 2017 Jun;65(5):883-891. doi: 10.1136/jim-2016-000339. Epub 2017 Jan 27.
7
Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.比较缓解复发型多发性硬化症患者疾病修饰疗法的疗效：系统评价和网络荟萃分析。
Mult Scler Relat Disord. 2016 Sep;9:23-30. doi: 10.1016/j.msard.2016.06.001. Epub 2016 Jun 8.
8
Laquinimod for multiple sclerosis.用于治疗多发性硬化症的拉喹莫德。
Cochrane Database Syst Rev. 2013 Aug 6;2013(8):CD010475. doi: 10.1002/14651858.CD010475.pub2.
9
Rituximab for relapsing-remitting multiple sclerosis.利妥昔单抗用于复发缓解型多发性硬化症。
Cochrane Database Syst Rev. 2013 Dec 6;2013(12):CD009130. doi: 10.1002/14651858.CD009130.pub3.
10
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.干扰素β与醋酸格拉替雷治疗复发缓解型多发性硬化症的对比
Cochrane Database Syst Rev. 2016 Nov 24;11(11):CD009333. doi: 10.1002/14651858.CD009333.pub3.
引用本文的文献
1
A Real-World Prospective Multiple Sclerosis Pregnancy Registry in the United States: PREG-MS.美国一个真实世界的前瞻性多发性硬化症妊娠登记处：PREG-MS。
Neurol Clin Pract. 2025 Apr;15(2):e200425. doi: 10.1212/CPJ.0000000000200425. Epub 2025 Jan 10.
2
Fingolimod Inhibits Exopolysaccharide Production and Regulates Relevant Genes to Eliminate the Biofilm of .芬戈莫德抑制胞外多糖的产生并调控相关基因消除 生物膜
Int J Mol Sci. 2024 Jan 23;25(3):1397. doi: 10.3390/ijms25031397.
3
The efficacy and safety of oral disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review.复发缓解型多发性硬化症口服疾病修正疗法的疗效与安全性：一项系统评价。
Curr J Neurol. 2020 Jul 5;19(3):138-145. doi: 10.18502/cjn.v19i3.5427.
4
Higher throughput workflow with sensitive, reliable and automatic quantification of myelination in vitro suitable for drug screening.具有更高通量工作流程的体外髓鞘形成的敏感、可靠和自动定量分析，适用于药物筛选。
Sci Rep. 2023 Feb 18;13(1):2883. doi: 10.1038/s41598-023-29333-1.
5
Molecular Hydrogen: an Emerging Therapeutic Medical Gas for Brain Disorders.分子氢：一种用于脑部疾病的新兴治疗性医用气体。
Mol Neurobiol. 2023 Apr;60(4):1749-1765. doi: 10.1007/s12035-022-03175-w. Epub 2022 Dec 26.
6
Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses.口服髓鞘少突胶质细胞糖蛋白通过诱导Th2/Treg细胞和抑制Th1/Th17免疫反应减轻实验性自身免疫性脑脊髓炎。
Curr Issues Mol Biol. 2022 Nov 18;44(11):5728-5740. doi: 10.3390/cimb44110388.
7
Fingolimod Promotes Antibacterial Effect of Doripenem against Carbapenem-Resistant .芬戈莫德增强多利培南对耐碳青霉烯类细菌的抗菌作用
Antibiotics (Basel). 2022 Aug 2;11(8):1043. doi: 10.3390/antibiotics11081043.
8
Delayed Maturation of Oligodendrocyte Progenitors by Microgravity: Implications for Multiple Sclerosis and Space Flight.微重力导致少突胶质前体细胞成熟延迟：对多发性硬化症和太空飞行的影响
Life (Basel). 2022 May 27;12(6):797. doi: 10.3390/life12060797.
9
Efficacy and safety of rituximab in patients with multiple sclerosis: An observational study at a tertiary center in Makkah, Saudi Arabia.利妥昔单抗治疗多发性硬化症患者的疗效和安全性：沙特阿拉伯麦加一家三级中心的观察性研究。
Neurosciences (Riyadh). 2022 Apr;27(2):65-70. doi: 10.17712/nsj.2022.2.20210122.
10
A Quantitative Synthesis of Eight Decades of Global Multiple Sclerosis Research Using Bibliometrics.使用文献计量学对八十年来全球多发性硬化症研究进行的定量综合分析。
Front Neurol. 2022 Feb 24;13:845539. doi: 10.3389/fneur.2022.845539. eCollection 2022.
本文引用的文献
1
Placebo-controlled trial of oral laquinimod for multiple sclerosis.安慰剂对照口服拉喹莫德治疗多发性硬化症的临床试验。
N Engl J Med. 2012 Mar 15;366(11):1000-9. doi: 10.1056/NEJMoa1104318.
2
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.使用那他珠单抗治疗的患者进行进行性多灶性白质脑病的风险分层。
Mult Scler. 2012 Feb;18(2):143-52. doi: 10.1177/1352458511435105.
3
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.REFLEX 研究：在首次临床脱髓鞘事件提示多发性硬化的患者中比较皮下注射干扰素β-1a 的两种给药频率：一项 3 期随机对照试验。
Lancet Neurol. 2012 Jan;11(1):33-41. doi: 10.1016/S1474-4422(11)70262-9. Epub 2011 Dec 4.
4
Emerging therapies for treatment of multiple sclerosis.新兴疗法治疗多发性硬化症。
J Inflamm Res. 2010;3:53-9. doi: 10.2147/jir.s6558. Epub 2010 Jul 23.
5
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.奥瑞珠单抗治疗复发缓解型多发性硬化症：一项 2 期、随机、安慰剂对照、多中心试验。
Lancet. 2011 Nov 19;378(9805):1779-87. doi: 10.1016/S0140-6736(11)61649-8. Epub 2011 Oct 31.
6
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.随机试验口服特立氟胺治疗复发型多发性硬化症。
N Engl J Med. 2011 Oct 6;365(14):1293-303. doi: 10.1056/NEJMoa1014656.
7
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort.多发性硬化症患者用阿仑单抗治疗后的自身免疫性疾病：一项多中心队列研究。
Neurology. 2011 Aug 9;77(6):573-9. doi: 10.1212/WNL.0b013e318228bec5. Epub 2011 Jul 27.
8
The mechanism of action of interferon-β in relapsing multiple sclerosis.干扰素-β在复发型多发性硬化症中的作用机制。
CNS Drugs. 2011 Jun 1;25(6):491-502. doi: 10.2165/11591110-000000000-00000.
9
Immune tolerance in multiple sclerosis.多发性硬化症的免疫耐受。
Immunol Rev. 2011 May;241(1):228-40. doi: 10.1111/j.1600-065X.2011.01016.x.
10
Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.醋酸格拉替雷治疗多发性硬化症：作用机制的新观点。
CNS Drugs. 2011 May;25(5):401-14. doi: 10.2165/11588120-000000000-00000.
Zotero 插件